{
    "clinical_study": {
        "@rank": "95933", 
        "arm_group": [
            {
                "arm_group_label": "LEO 43204", 
                "arm_group_type": "Experimental", 
                "description": "Open-label, dose-escalation, 2-day treatment"
            }, 
            {
                "arm_group_label": "LEO 43204 Dose X", 
                "arm_group_type": "Experimental", 
                "description": "LEO 43204 dose X once daily for two consecutive days"
            }, 
            {
                "arm_group_label": "LEO 43204 Dose Y", 
                "arm_group_type": "Experimental", 
                "description": "LEO 43204 dose Y once daily for two days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo once daily for two days"
            }
        ], 
        "brief_summary": {
            "textblock": "Part 1:  To identify Maximum Tolerated Dose (MTD) levels of LEO 43204 after once daily\n      treatment for two consecutive days\n\n      Part 2:  To evaluate the efficacy of LEO 43204 in two doses after once daily treatment for\n      two consecutive days compared to vehicle"
        }, 
        "brief_title": "Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Actinic Keratosis", 
        "condition_browse": {
            "mesh_term": [
                "Keratosis", 
                "Keratosis, Actinic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Part 1: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the arm\n\n          -  Part 2: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the\n             extremities or trunk\n\n        Exclusion Criteria:\n\n          -  Location of the treatment area\n\n               -  within 5 cm of an incompletely healed wound\n\n               -  within 5 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma\n                  (SCC)\n\n          -  Prior treatment with ingenol mebutate gel on the treatment area\n\n          -  Lesions in the treatment areas that have:\n\n               -  atypical clinical appearance (e.g., hypertrophic, hyperkeratotic or cutaneous\n                  horns) and/or\n\n               -  recalcitrant disease (e.g., did not respond to cryotherapy on two previous\n                  occasions)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "227", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02120456", 
            "org_study_id": "LP0084-1015"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LEO 43204", 
                    "LEO 43204 Dose X", 
                    "LEO 43204 Dose Y"
                ], 
                "intervention_name": "LEO 43204", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 21, 2014", 
        "number_of_arms": "4", 
        "official_title": "Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis", 
        "overall_contact": {
            "email": "aruna.sharma@leo-pharma.com", 
            "last_name": "Aruna Sharma", 
            "phone": "905-747-2354"
        }, 
        "overall_official": {
            "affiliation": "Mount Sinai School of Medicine, Dermatology Faculty", 
            "last_name": "Gary Goldenberg, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Part 1:  Dose Limiting Toxicity up to and including Day 8", 
                "safety_issue": "Yes", 
                "time_frame": "8 days"
            }, 
            {
                "description": "Percent reduction in AK count from baseline to Week 8", 
                "measure": "Part 2:  Percent Reduction in AK Count", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02120456"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Part 2:  Complete Clearance of AKs", 
                "safety_issue": "No", 
                "time_frame": "8 Weeks"
            }, 
            {
                "description": "Partial clearance of AKs at Week 8, defined as at least 75% reduction from baseline in AK count", 
                "measure": "Part 2:  Partial Clearance of AKs", 
                "safety_issue": "No", 
                "time_frame": "8 Weeks"
            }
        ], 
        "source": "LEO Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LEO Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}